Sun Pharma’s specialty portfolio, Organon deal to drive growth
· economictimes.indiatimes.com
Sun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines. The company anticipates medium-term growth from therapies like Ilumya and ongoing innovative projects. Although profitability was affected by acquisition and litigation costs, the domestic market share increased to 8.6% from last year. R&D investments are expected to rise in the second half of FY27 as development accelerates.
ET Bureau
Live Events
as a Reliable and Trusted News Source Addas a Reliable and Trusted News Source Add Now!
(You can now subscribe to our
(You can now s...